Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Cytosorbents Corp

Get SEC filing alerts via email and in your feed for Cytosorbents Corp

CTSO

Cytosorbents Corp

About Cytosorbents Corp

CytoSorbents Corporation specializes in blood purification technologies for critical care, cardiac surgery, and organ transplantation. Its flagship product, CytoSorb, removes inflammatory mediators, toxins, and blood thinners from blood using porous polymer beads. The company develops and markets extracorporeal cartridges and devices globally, targeting high-risk patients with conditions like sepsis, COVID-19, organ failure, and bleeding risks, with a focus on improving clinical outcomes and reducing healthcare costs.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Cytosorbents Corp

1
1
Cytosorbents Corp CytoSorbents Reports Q1 2026 Financial Results with Revenue of $8.9 Million

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Cytosorbents Corp CytoSorbents Reports $37.1M Revenue and $8.2M Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Cytosorbents Corp Cytosorbents Reports 10.1% Revenue Growth in Q3 2025, Improves Operational Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Cytosorbents Corp CytoSorbents Reports 8.8% Revenue Growth to $9.6 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Cytosorbents Corp CytoSorbents Reports Q1 2025 Financial Results with $8.7M Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Cytosorbents Corp Cytosorbents Reports $35.6 Million Revenue for Fiscal Year 2024, Achieves 15% Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Cytosorbents Corp CytoSorbents Reports 7% Revenue Growth, Improved Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments